Pipeline Overview

Innovative Drugs Designed to Improve Patients’ Lives

Nurix is advancing three internally discovered and wholly owned clinical-stage drug-candidates designed to treat patients with hematologic malignancies, solid tumors and inflammatory diseases. Nurix’s pipeline comprises both Targeted Protein Degraders to eliminate disease causing proteins and E3 ligase inhibitors that target key control elements in immune regulation (Targeted Protein Elevation). Drug discovery alliances with Gilead Sciences, Sanofi, and Pfizer further enhance our pipeline, each focusing on the discovery and development of Targeted Protein Degraders and Degrader-Antibody Conjugates against a set of unique targets.

Drug Program	MOA	Target/Delivery	Therapeutic Area	Discovery - Lead Op	IND enabling	Phase 1a	Phase 1b
Hematology/Oncology
NX-5948	TPD	BTK	B-cell malignancies
NX-2127	TPD	BTK + IKZF	B-cell malignancies
NX-1607	TPE	CBL-B	Immuno-oncology
Multiple	TPD	Undisclosed	Undisclosed
Multiple	TPD	Undisclosed	Undisclosed
Multiple	TPD	Undisclosed	Undisclosed
Multiple	DAC	Undisclosed	Oncology
Drug Program	MOA	Target/Delivery	Therapeutic Area	Discovery - Lead Op	IND enabling	Phase 1a	Phase 1b
Inflammation & Immunology
NX-5948	TPD	BTK	Inflammation/autoimmune
NX‑0479/GS‑6791	TPD	IRAK4	Rheumatoid arthritis and other inflammatory diseases
STAT6 degrader	TPD	STAT6	Type 2 inflammatory diseases
Undisclosed	TPD	Undisclosed	Inflammation/autoimmune

Hematology/Oncology

NX-5948 - TPDBTK - B-cell malignancies

Preclinical

IND-Enabling

Phase 1a

Phase 1b

NX-2127 - TPDBTK + IKZF - B-cell malignancies

Preclinical

IND-Enabling

Phase 1a

Phase 1b

NX-1607 - TPECBL-B - Immuno-oncology

Preclinical

IND-Enabling

Phase 1a

Phase 1b

Multiple - TPDUndisclosed - Undisclosed

Preclinical

IND-Enabling

Phase 1a

Phase 1b

Multiple - TPDUndisclosed - Undisclosed

Preclinical

IND-Enabling

Phase 1a

Phase 1b

Multiple - TPDUndisclosed - Undisclosed

Preclinical

IND-Enabling

Phase 1a

Phase 1b

Multiple - DACUndisclosed - Oncology

Preclinical

IND-Enabling

Phase 1a

Phase 1b

Inflammation & Immunology

NX-5948 - TPDBTK - Inflammation/autoimmune

Preclinical

IND-Enabling

Phase 1a

Phase 1b

NX‑0479/GS‑6791 - TPDIRAK4 - Rheumatoid arthritis and other inflammatory diseases

Preclinical

IND-Enabling

Phase 1a

Phase 1b

STAT6 degrader - TPDSTAT6 - Type 2 inflammatory diseases

Preclinical

IND-Enabling

Phase 1a

Phase 1b

Undisclosed - TPDUndisclosed - Inflammation/autoimmune

Preclinical

IND-Enabling

Phase 1a

Phase 1b